fda semaglutide ruling Compound versions of GLP-1 drugs for weight loss halted by The FDA Wins. The OFA

GLP-1 Insurance Coverage Landscape GLP-1 drugs coverage depends on payer type (commercial/employer plans, Medicare, Medicaid) and on the indication (diabetes vs obesity)

Oral semaglutide, the first ingestible glucagon-like peptide-1 receptor agonist: Could it be a magic bullet for type 2 diabetes

21 GulloF.CerianiM.DAloiaA.WankeE.ConstantiA.CostaB.et al (2017)

To evaluate the effects of GLP-1(2836) on cellular bioenergetics, we used the Seahorse extracellular flux analyzer and performed glycolysis stress tests to measure glycolysis and glycolytic capacity and reserve in intact caSMCs

Oral administration of meclofenoxate to rats (100 mg/kg, daily for 37 days) significantly improved memory impairment, and reduced neuronal damage, proinflammatory mediator levels, and oxidative stress to normal levels